Log In
Print this Print this

Glycoconjugate ExPEC vaccine

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionBioconjugate vaccine against extra-intestinal pathogenic Escherichia coli (ExPEC)
Molecular Target
Mechanism of Action 
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationEscherichia
Indication DetailsPrevent infections caused by ExPEC
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today